In a report released today, Florent Cespedes from Bernstein maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...

Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. | Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that ...

Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The ...

Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk denies wrongdoing, pledges affordable insulin Jan 27 (Reuters) - Novo Nordisk (NOVOb ...

SNY and RHHBY announce fourth-quarter earnings. NVO's novel obesity medicine, amycretin, shows superior weight loss in study.

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes ...

This is in sharp contrast to its big rival in diabetes, Novo Nordisk, which turned in impressive growth during the period. The main culprit for Sanofi's bad news is insulin blockbuster Lantus ...

Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...

The Senate Finance Committee advances the nomination of Robert F. Kennedy Jr. for HHS Secretary amid a party-line vote. Read ...

If California patients pay more than $35 per month for insulin now, it’s in large part because PBMs have rigged the system in ...